This white paper provides a data driven analysis of the rapidly evolving Belgian anti obesity medication (AOM) market, combining real world prescription data (LRx) with national patient survey insights. It explores prescribing dynamics, patient pathways, persistence challenges, and the shifting roles of GPs, pharmacists, and specialists in obesity care.

Key takeaways:

Belgium is at an inflection point in AOM adoption, with growing demand and expanding prescriber base. Yet, high early discontinuation highlights critical gaps in patient support and care coordination. Addressing persistence, enabling HCP collaboration, and tailoring approaches to distinct patient personas will be key to unlocking long-term impact.